Study Shows AKT1 E17K a Targetable Mutation Through AKT Inhibition Across Various Cancer Types
November 7th 2017Amultihistology basket study proved the targetability of the <em>AKT1 E17K</em> mutation in human cancers by treating patients with various types of cancer harboring an <em>AKT1 E17K </em>mutation with AZD5363, an oral pan-AKT inhibitor, according to findings published in the <em>Journal of Clinical Oncology</em>.
Therapeutic Options Developing for Nondriver NSCLC, But Challenges Remain
September 1st 2017Corey Langer, MD, provides details on the goals and implications of the KEYNOTE-021 trial. Moreover, he discusses the current arena in NSCLC treatment and the obstacles that remain in treating patients without driver mutations effectively.